August 15, 2025

Indocyanine Green Angiography Shows Potential in Leak Prevention

The benefit might be in preventing grade A or B leaks, the researchers posited.

Conexiant

August 15, 2025

Autoimmune Diseases Tied to Different Digestive Cancer Risks

Researchers examined celiac disease, SLE, MS, and T1D in relation to cancers of the pancreas, stomach, esophagus, small intestine, colon, rectum, liver, and gallbladder.

Conexiant

August 14, 2025

Greater Variety of Flavonoids Tied to Lower Chronic Disease

Higher diversity and quantity of dietary flavonoid intake were each linked to reduced risks of mortality and major chronic diseases in a large population-based study.

Conexiant

August 11, 2025

FDA OKs Bioequivalent Iron Sucrose for CKD Anemia

The FDA has approved a bioequivalent iron sucrose injection for treating iron deficiency anemia in patients with chronic kidney disease.

Conexiant

August 01, 2025

Physicians Urged to Defend USPSTF Role

The Colorectal Cancer Alliance and partners are urging the Department of Health and Human Services to preserve U.S. Preventive Services Task Force’s evidence-based role in safeguarding access to no-cost colorectal cancer screening.

Conexiant

April 26, 2024

FDA Grants Orphan Drug Designation to Novel Pancreatic Cancer Drug Candidate

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the novel drug candidate FL118 for the treatment of patients with pancreatic cancer.

Conexiant

April 26, 2024

Irinotecan Liposome Approved by FDA for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma.

Conexiant

October 18, 2024

FDA Approves New Gastric Cancer Therapy

The FDA has approved Vyloy, a monoclonal antibody, for the treatment of gastric cancer in combination with chemotherapy, marking a significant step in targeted therapy for this disease.

Reuters

November 07, 2024

Zinc: Missing Link in HE Management?

Study reveals stark survival contrast: cirrhotic patients with normal zinc levels showed 86% survival rate versus significantly poorer outcomes in zinc-deficient patients (35.56 ± 11.65 mcg/dL, P<.0001), suggesting a potentially modifiable risk factor in hepatic encephalopathy management.

Conexiant